Table 2 Treatment-related adverse events experienced by ≥ 15% of participants in ≥ 1 arm by preferred term (safety set, phase 1b/2)
|  | Doublet Arms (Arms 1A and 2A) n = 37 | Triplet Arms (Arms 1B and 2B) n = 38 |
|---|---|---|
TRAEs, n (%) | ||
 Dermatitis acneiform | 19 (51.4) | 18 (47.4) |
 Blood creatine phosphokinase increased | 18 (48.6) | 15 (39.5) |
 Diarrhea | 17 (45.9) | 15 (39.5) |
 Rash | 8 (21.6) | 15 (39.5) |
 Fatigue | 11 (29.7) | 11 (28.9) |
 Nausea | 10 (27.0) | 11 (28.9) |
 Edema peripheral | 11 (29.7) | 9 (23.7) |
 Vomiting | 8 (21.6) | 11 (28.9) |
 Decreased appetite | 10 (27.0) | 8 (21.1) |
 Asthenia | 8 (21.6) | 7 (18.4) |
 Pruritus | 5 (13.5) | 10 (26.3) |
 Ejection fraction decreased | 5 (13.5) | 7 (18.4) |
 Aspartate aminotransferase increased | 3 (8.1) | 7 (18.4) |
 Dry skin | 2 (5.4) | 7 (18.4) |
 Pyrexia | 2 (5.4) | 7 (18.4) |
 Alanine aminotransferase increased | 2 (5.4) | 6 (15.8) |
 Cough | 1 (2.7) | 6 (15.8) |
 Dry mouth | 2 (5.4) | 5 (13.2) |
 Dyspnea | 3 (8.1) | 4 (10.5) |
 Dysgeusia | 1 (2.7) | 4 (10.5) |
 Visual impairment | 2 (5.4) | 3 (7.9) |
 Dizziness | 2 (5.4) | 2 (5.3) |
 Pneumonitis | 0 | 4 (10.5) |
 Rash pruritic | 3 (8.1) | 0 |